In patients with eGFR lower than 60 mL/min/1.73 m2, SGLT2 inhibitors tended to reduce the risk of stroke (HR, 0.75; 95% CI, 0.55–1.02; p = 0.066) with some heterogeneity (I2 = 58%; p = 0.14) (Supplementary Fig. 10). This evidence concerns the gene SLC5A2 and Stroke.